To characterize the immune response specifically due to SARS-CoV-2 vaccination, we evaluated the level of SARS-CoV-2 anti-spike B cells (expressed as counts and relative frequencies) in MS patients and controls at the four time points. Here, CHMP5 is linked to myeloid sarcoma.